Medicus Pharma Shifted SkinJect Focus to Gorlin Syndrome

The company will now target a rare genetic skin cancer in its upcoming clinical trials.

Updated on Sept. 27, 2026 in Cancer

Bold flat-color editorial illustration showing a hexagonal microneedle array, representing precision medical technology for clinical trials. — Medicus Pharma is narrowing its clinical trial focus for its SkinJect microneedle patch exclusively to patients diagnosed with rare Gorlin syndrome. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize rare-disease drug development over treatments for common conditions?

Medicus Pharma has restricted the development of its SkinJect patch, a localized chemotherapy delivery system, to focus exclusively on patients with Gorlin syndrome. This shift follows regulatory feedback and a review of the company's clinical development strategy for treating active basal cell carcinoma.

Why it matters

By narrowing its scope to this rare genetic condition, the company aims to optimize its clinical spending and address regulatory requirements for its drug development programs. This change dictates the future path for patients currently tracking potential new, non-surgical options for skin lesion management.

The SKNJCT-003 Phase 2 study identified a 200-microgram doxorubicin-loaded patch as the proposed dose for further investigation. Future efficacy and safety data will be generated in the upcoming SKNJCT-005 Phase 2b clinical study.

The players

Medicus Pharma

A Philadelphia-based pharmaceutical firm focused on developing clinical-stage therapies for oncology and dermatological conditions.

FDA

The federal agency responsible for overseeing the safety and efficacy of medical products and drug-trial protocols in the United States.

The details

The SkinJect technology utilizes a dissolvable microneedle array to deliver doxorubicin directly into skin lesions. By applying the chemotherapy locally, the system aims to treat basal cell carcinoma while minimizing systemic exposure. Medicus Pharma narrowed its program to focus on the 11,000 U.S. individuals affected by the rare, autosomal dominant condition of Gorlin syndrome.

July 2026: The FDA issued a Study May Proceed letter.
September 8, 2026: Medicus outlined its updated capital-allocation strategy.
September 27, 2026: The report on the program shift was published.

Cancer
Sept. 22
FDA Requested More Survival Data for Tovecimig
Cancer
Sept. 21
FDA Conditionally Accepted Name for New Cancer Drug
Allergies
Sept. 18
FDA Approved New Therapy for Sanfilippo Syndrome Type A

Health Landscape

This pivot reflects a broader industry trend of prioritizing clinical programs that align with orphan drug designation pathways. Such strategies are frequently employed to navigate the regulatory requirements set by the FDA for treatments targeting smaller patient populations.

Patients with Gorlin syndrome should monitor for updates regarding clinical trial recruitment to understand if the local therapy fits their care needs. Always discuss potential enrollment in clinical studies or changes to your treatment plan with your dermatologist or oncologist.

The takeaway

The transition to a rare-disease focus highlights the importance of matching targeted delivery technology with specific patient needs. Patients and their families should keep an eye on upcoming study results for the 200-microgram doxorubicin patch as an indicator of future clinical viability.